InterMune Inc. raised $150 million in a private placement of convertible senior notes as part of a plan to reduce its burn rate and narrow its focus in two therapeutic areas. (BioWorld Today)
Vion Pharmaceuticals Inc. discontinued enrollment of a Phase II study of Triapine as a single agent in patients with prostate cancer in order to focus its resources on the drug's more promising trials - those studying it as a combination therapy. (BioWorld Today)
